All In Biotech

Drug Trial Radar · NCT06066580

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

An Open-Label Extension Study to Assess the Long-term Effect of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

260

Planned (sponsor's estimate)

Start

Nov 2, 2023

Primary completion

Feb 2031

Study completion Feb 2031

Sponsor

Lead sponsor
Edgewise Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Oct 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy

Conditions

  • Becker Muscular Dystrophy

Interventions

  • SevasemtenDrug

    Sevasemten is administered orally once per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse events in those treated with sevasemtenTime frame: 55 Months
  2. Severity of adverse events in those treated with sevasemtenTime frame: 55 Months

Locations

48 sites in 12 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • UC San Diego

    La Jolla, California

  • UCLA Medical Center

    Los Angeles, California

  • UC Irvine Medical Center

    Orange, California

  • Stanford Neuroscience Health Center

    Palo Alto, California

  • UC Davis Medical Center

    Sacramento, California

  • UC Denver

    Aurora, Colorado

  • University of Florida

    Gainesville, Florida

  • Rare Disease Research

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Rochester Medical Center

    Rochester, New York

  • Rare Disease Research, LLC NC

    Hillsborough, North Carolina

  • University of Cincinnati Gardner Neuroscience Institute

    Cincinnati, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • National Neuromuscular Research Institute

    Austin, Texas

  • Neurology Rare Disease Center

    Denton, Texas

  • Virginia Commonwealth University Health

    Richmond, Virginia

  • St Vincent's Hospital

    Melbourne, Victoria, Australia

  • University Hospital Gent

    Ghent, Belgium, Belgium

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium, Belgium

  • Centre Hospitalier Régional de la Citadelle

    Liége, Belgium, Belgium

  • Rigshospitalet

    Copenhagen, Denmark

  • Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone

    Marseille, France, France

  • CHU de Nantes

    Nantes, France, France

  • CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires

    Nice, France, France

  • AP-HP Hopital Pitie-Salpetriere

    Paris, France, France

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen

    Munich, Germany, Germany

  • Hadassah University Hospital

    Jerusalem, Israel

  • Fondazione IRCCS Ca'Granda Ospedale Maggiore

    Milan, Italy, Italy

  • Azienda Ospedale - Università Padova

    Padova, Italy, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Italy, Italy

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Optimal Clinical Trials

    Auckland, New Zealand

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.